COR stock icon

Cencora
COR

$239.36
1.13%
 

About: Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Employees: 46,000

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 5 analysts
0
News positive %
of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

140% more call options, than puts

Call options by funds: $1.59B | Put options by funds: $660M

57% more first-time investments, than exits

New positions opened: 168 | Existing positions closed: 107

38% more capital invested

Capital invested by funds: $34.5B [Q4 2023] → $47.6B (+$13.1B) [Q1 2024]

26% more funds holding in top 10

Funds holding in top 10: 19 [Q4 2023] → 24 (+5) [Q1 2024]

14.61% more ownership

Funds ownership: 83.85% [Q4 2023] → 98.46% (+14.61%) [Q1 2024]

6% more funds holding

Funds holding: 1,056 [Q4 2023] → 1,117 (+61) [Q1 2024]

6% less repeat investments, than reductions

Existing positions increased: 383 | Existing positions reduced: 407

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$224
6%
downside
Avg. target
$257
7%
upside
High target
$280
17%
upside

5 analyst ratings

positive
80%
neutral
20%
negative
0%
Baird
David Rodgers
16%upside
$277
Outperform
Maintained
2 May 2024
Citigroup
Michael Rollins
17%upside
$280
Buy
Maintained
30 Apr 2024
Leerink Partners
Michael Cherny
9%upside
$261
Outperform
Initiated
26 Feb 2024
Mizuho
Omotayo Okusanya
6%downside
$224
Neutral
Maintained
5 Feb 2024
Barclays
Stephanie Davis
1%upside
$242
Overweight
Initiated
3 Jan 2024

Financial journalist opinion

Based on 5 articles about COR published over the past 30 days